GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET ANONIM SIRKETI Financials Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi
Equities
GENIL
TREGENL00024
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.9 TRY | -0.71% |
|
-6.68% | +19.24% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 4,605 | 15,514 | 14,064 |
| Enterprise Value (EV) 1 | 4,237 | 15,020 | 14,658 |
| P/E ratio | 11.4 x | 14.4 x | 30.9 x |
| Yield | 2.39% | 2.15% | - |
| Capitalization / Revenue | 1.84 x | 2.85 x | 1.73 x |
| EV / Revenue | 1.69 x | 2.76 x | 1.8 x |
| EV / EBITDA | 13.4 x | 19.5 x | 17.5 x |
| EV / FCF | 135,345,055 x | -55,964,319 x | -16,658,566 x |
| FCF Yield | 0% | -0% | -0% |
| Price to Book | 3.59 x | 5.56 x | 2.91 x |
| Nbr of stocks (in thousands) | 300,000 | 299,496 | 300,000 |
| Reference price 2 | 15.35 | 51.80 | 46.88 |
| Announcement Date | 3/4/22 | 3/3/23 | 4/5/24 |
1TRY in Million2TRY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,180 | 1,795 | 2,150 | 2,501 | 5,445 | 8,152 |
| EBITDA 1 | 91.45 | 210.6 | 245.7 | 316.9 | 768.8 | 836.3 |
| EBIT 1 | 79.32 | 194.9 | 226.2 | 273.4 | 712 | 575.5 |
| Operating Margin | 6.72% | 10.86% | 10.52% | 10.93% | 13.07% | 7.06% |
| Earnings before Tax (EBT) 1 | 7.038 | 159.1 | 216.8 | 301.4 | 1,073 | 262.4 |
| Net income 1 | 6.524 | 143.1 | 207 | 310.8 | 1,080 | 454.6 |
| Net margin | 0.55% | 7.97% | 9.63% | 12.43% | 19.84% | 5.58% |
| EPS | - | - | 4.141 | 1.343 | 3.601 | 1.515 |
| Free Cash Flow | - | 77.69 | -84.68 | 31.3 | -268.4 | -879.9 |
| FCF margin | - | 4.33% | -3.94% | 1.25% | -4.93% | -10.79% |
| FCF Conversion (EBITDA) | - | 36.89% | - | 9.88% | - | - |
| FCF Conversion (Net income) | - | 54.28% | - | 10.07% | - | - |
| Dividend per Share | - | - | - | 0.3667 | 1.111 | - |
| Announcement Date | 7/12/21 | 7/12/21 | 7/12/21 | 3/4/22 | 3/3/23 | 4/5/24 |
1TRY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 161 | 78.6 | 109 | - | - | 594 |
| Net Cash position 1 | - | - | - | 368 | 494 | - |
| Leverage (Debt/EBITDA) | 1.759 x | 0.3731 x | 0.4426 x | - | - | 0.7102 x |
| Free Cash Flow | - | 77.7 | -84.7 | 31.3 | -268 | -880 |
| ROE (net income / shareholders' equity) | - | 79.6% | 51.6% | 33.7% | 53.2% | 9.23% |
| ROA (Net income/ Total Assets) | - | 25% | 17.3% | 10.7% | 15.3% | 5.13% |
| Assets 1 | - | 571.4 | 1,200 | 2,908 | 7,044 | 8,868 |
| Book Value Per Share | - | - | 11.10 | 4.280 | 9.310 | 16.10 |
| Cash Flow per Share | - | - | 1.170 | 1.730 | 1.300 | 0.2200 |
| Capex 1 | 7.22 | 38.2 | 84.1 | 125 | 312 | 528 |
| Capex / Sales | 0.61% | 2.13% | 3.91% | 4.98% | 5.74% | 6.47% |
| Announcement Date | 7/12/21 | 7/12/21 | 7/12/21 | 3/4/22 | 3/3/23 | 4/5/24 |
1TRY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +19.24% | 524M | |
| +31.06% | 682B | |
| +30.35% | 586B | |
| -3.42% | 364B | |
| +18.02% | 327B | |
| +4.27% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.12% | 165B |
- Stock Market
- Equities
- GENIL Stock
- Financials Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi